These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://deborahmagz988770.dailyhitblog.com/44674142/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide